Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 3,167 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.99, for a total value of $18,970.33. Following the completion of the transaction, the chief technology officer now owns 1,756,481 shares in the company, valued at approximately $10,521,321.19. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Sight Sciences Stock Down 2.9 %
Shares of SGHT opened at $6.00 on Friday. The stock has a fifty day simple moving average of $6.54 and a two-hundred day simple moving average of $6.23. The company has a quick ratio of 10.50, a current ratio of 11.01 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $298.54 million, a PE ratio of -5.36 and a beta of 2.71. Sight Sciences, Inc. has a 52-week low of $1.04 and a 52-week high of $8.45.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.06. The firm had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same period last year, the company earned ($0.30) EPS. As a group, equities analysts forecast that Sight Sciences, Inc. will post -1 EPS for the current year.
Institutional Trading of Sight Sciences
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of hedge funds and other institutional investors have recently modified their holdings of SGHT. RTW Investments LP purchased a new position in Sight Sciences during the 4th quarter valued at about $850,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sight Sciences by 51.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company's stock valued at $141,000 after acquiring an additional 9,106 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Sight Sciences during the 1st quarter valued at about $59,000. Vanguard Group Inc. boosted its holdings in Sight Sciences by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company's stock valued at $8,218,000 after acquiring an additional 81,768 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Sight Sciences by 25.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company's stock valued at $1,991,000 after acquiring an additional 76,549 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have weighed in on SGHT. Citigroup raised their price objective on Sight Sciences from $6.00 to $6.50 and gave the company a "neutral" rating in a report on Wednesday, July 10th. Lake Street Capital began coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a "buy" rating and a $10.00 price objective on the stock. Morgan Stanley raised their target price on Sight Sciences from $5.40 to $6.50 and gave the stock an "equal weight" rating in a research note on Monday, July 15th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.25.
Read Our Latest Research Report on SGHT
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
